ERBB2 and neoplasm: It was also approved for the treatment of adult patients with advanced NSCLC whose tumours have an activated HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy, and for adult patients with advanced HER2-positive gastric or gastro-oesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen [121].